EVP & Chief Financial Officer, Hua Medicine
Mr. George Lin, J.D., a healthcare veteran brings with him over 18 years of investment banking and legal experience working with numerous private and public companies globally. Prior to joining Hua Medicine, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and Head of Hong Kong and Taiwan Investment Banking for Bank of America Merrill Lynch based in Hong Kong. As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was previously based in Los Angeles and San Francisco before moving to Hong Kong in 2007. His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the United States and Europe. In the last 10 years alone, Mr. Lin has led M&A transactions valued (in aggregate) in excess of US$20 billion and raised financings valued (in aggregate) at over US$40 billion. Since April 2018, Mr. Lin has served as a member of the Biotech Advisory Panel of the Hong Kong Stock Exchange.
Prior to Bank of America Merrill Lynch, Mr. Lin also worked at Credit Suisse as an investment banker in their Hong Kong, San Francisco and Los Angeles offices, and at O’Melveny & Myers LLP as a corporate attorney in their Los Angeles Office. Since November 2020, Mr. George Lin has served as an independent non-executive director at Shanghai Bio-heart Biological Technology Co., Ltd., a company first listed on the main board of the Stock Exchange of Hong Kong (stock code: 2185) in December 2021. Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis and a Juris Doctor degree from The University of Chicago Law School.